SLC51A

Summary

SLC51A (solute carrier family 51 member A, HGNC:29955) is a protein-coding gene on chromosome 3q29, encoding Organic solute transporter subunit alpha (Q86UW1). Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood.

Predicted to enable protein heterodimerization activity; protein homodimerization activity; and transmembrane transporter activity. Involved in bile acid secretion. Located in basolateral plasma membrane. Implicated in progressive familial intrahepatic cholestasis.

Source: NCBI Gene 200931 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cholestasis, progressive familial intrahepatic, 6 (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 88 total — 1 pathogenic
• Phenotypes (HPO): 12
• Druggable target: yes
• MANE Select transcript: NM_152672

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29955
Approved symbol	SLC51A
Name	solute carrier family 51 member A
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	OSTalpha, SLC51A1
Ensembl gene	ENSG00000163959
Ensembl biotype	protein_coding
OMIM	612084
Entrez	200931

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 7 protein_coding, 7 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000296327, ENST00000415111, ENST00000416660, ENST00000428985, ENST00000442203, ENST00000471430, ENST00000472653, ENST00000475271, ENST00000475672, ENST00000476129, ENST00000479732, ENST00000484407, ENST00000492794, ENST00000496737, ENST00000900647, ENST00000900648, ENST00000900649

RefSeq mRNA: 1 — MANE Select: NM_152672 NM_152672

CCDS: CCDS3314

Canonical transcript exons

ENST00000296327 — 9 exons

Exon	Start	End
ENSE00001333743	196227664	196227737
ENSE00001333744	196226965	196227119
ENSE00001731902	196216534	196216750
ENSE00003489073	196232419	196232524
ENSE00003497730	196228809	196228920
ENSE00003511981	196233063	196233427
ENSE00003513914	196217842	196217936
ENSE00003523719	196229915	196230061
ENSE00003542186	196228115	196228273

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 99.40.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.5388 / max 97.2266, expressed in 113 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40717	0.2483	57
40716	0.1664	46
40715	0.0379	16
40720	0.0328	10
40719	0.0257	8
40718	0.0196	12
40721	0.0080	3

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	99.40	gold quality
mucosa of transverse colon	UBERON:0004991	97.73	gold quality
right lobe of liver	UBERON:0001114	97.65	gold quality
liver	UBERON:0002107	94.85	gold quality
nasal cavity epithelium	UBERON:0005384	94.80	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.19	gold quality
jejunal mucosa	UBERON:0000399	92.87	gold quality
small intestine	UBERON:0002108	91.81	gold quality
duodenum	UBERON:0002114	91.71	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	90.41	gold quality
right testis	UBERON:0004534	90.19	gold quality
sperm	CL:0000019	89.94	gold quality
transverse colon	UBERON:0001157	89.89	gold quality
left testis	UBERON:0004533	89.26	gold quality
right adrenal gland	UBERON:0001233	89.03	gold quality
left adrenal gland cortex	UBERON:0035825	88.75	gold quality
left adrenal gland	UBERON:0001234	88.40	gold quality
right adrenal gland cortex	UBERON:0035827	88.26	gold quality
testis	UBERON:0000473	87.17	gold quality
adrenal cortex	UBERON:0001235	87.04	gold quality
adrenal gland	UBERON:0002369	86.75	gold quality
palpebral conjunctiva	UBERON:0001812	85.40	gold quality
adrenal tissue	UBERON:0018303	84.11	gold quality
bone marrow cell	CL:0002092	83.47	gold quality
intestine	UBERON:0000160	83.47	gold quality
right ovary	UBERON:0002118	82.38	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.05	gold quality
granulocyte	CL:0000094	82.03	gold quality
gastrocnemius	UBERON:0001388	82.03	gold quality
muscle of leg	UBERON:0001383	81.91	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR0B2, NR1H3, NR1H4, NR5A2

miRNA regulators (miRDB)

18 targeting SLC51A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-452-3P	99.01	66.25	1241
HSA-MIR-10395-3P	98.10	66.70	1726
HSA-MIR-630	97.50	66.38	921
HSA-MIR-643	97.35	67.91	805
HSA-MIR-1202	97.19	66.43	827
HSA-MIR-3972	97.19	66.46	808
HSA-MIR-3126-5P	96.87	65.83	912
HSA-MIR-6875-5P	96.87	65.49	958
HSA-MIR-3194-5P	96.80	64.90	1027

Literature-anchored findings (GeneRIF, showing 13)

• OSTalpha has roles in biological transport and is widely expressed in human tissues (PMID:12719432)
• overexpression of human OSTalpha and OSTbeta facilitated the uptake of conjugated chenodeoxycholate and the activation of FXR target genes (PMID:16251721)
• OSTalpha/OSTbeta expression is induced by bile acids through ligand-dependent transactivation of both OST genes by the nuclear bile acid receptor/farnesoid X receptor (FXR). (PMID:16269519)
• the selective localization of OSTalpha and OSTbeta to the basolateral plasma membrane of epithelial cells responsible for bile acid and sterol reabsorption. (PMID:16317684)
• These results indicate that expression of Ostalpha and Ostbeta are highly regulated in response to cholestasis and that this response is dependent on the FXR bile acid receptor. (PMID:16423920)
• Demonstrate association of OST-alpha and OST-beta to determine trafficking to plasma membrane and activity. (PMID:17332473)
• The mRNA expression of OSTalpha-OSTbeta was significantly reduced (OSTalpha: 3.3-fold, P = 0.006; OSTbeta: 2.6-fold, P = 0.03) in normal-weight but not overweight gallstone carriers (PMID:18469300)
• human OSTalpha is a glycoprotein that requires interaction with OSTbeta to reach the plasma membrane. However, glycosylation of OSTalpha is not necessary for interaction with the beta subunit or for membrane localization . (PMID:18847488)
• The present report summarizes the evidence for a pleiotropic role of Ostalpha-Ostbeta in different tissues. (PMID:21691099)
• Ostbeta is required for both proper trafficking of Ostalpha and formation of the functional transport unit, and identify specific residues of Ostbeta critical for these processes. (PMID:22535958)
• Hepatic OSTalpha-OSTbeta expression is induced by hypoxia. (PMID:24703425)
• SLC51A expression is significantly upregulated in human masticatory mucosa during wound healing (PMID:28005267)
• A Genome-wide Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic Community Health Study/Study of Latinos. (PMID:33031748)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slc51a	ENSMUSG00000035699
rattus_norvegicus	Slc51a	ENSRNOG00000001765
drosophila_melanogaster	Tmep	FBGN0035236

Paralogs (3): TMEM184C (ENSG00000164168), TMEM184A (ENSG00000164855), TMEM184B (ENSG00000198792)

Protein

Protein identifiers

Organic solute transporter subunit alpha — Q86UW1 (reviewed: Q86UW1)

Alternative names: Solute carrier family 51 subunit alpha

All UniProt accessions (5): C9J2I5, Q86UW1, F8WBV2, H7C351, H7C3V2

UniProt curated annotations — full annotation on UniProt →

Function. Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids (taurocholate). Taurine conjugates are transported more efficiently across the basolateral membrane than glycine-conjugated bile acids. Can also transport steroids such as estrone 3-sulfate and dehydroepiandrosterone 3-sulfate, therefore playing a role in the enterohepatic circulation of sterols. Able to transport eicosanoids such as prostaglandin E2.

Subunit / interactions. Interacts with SLC51B. The Ost-alpha/Ost-beta complex is a heterodimer composed of alpha (SLC51A) and beta (SLC51B) subunit.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Tissue specificity. Widely expressed with a high expression in ileum. Expressed in testis, colon, liver, small intestine, kidney, ovary and adrenal gland; and at low levels in heart, lung, brain, pituitary, thyroid gland, uterus, prostate, mammary gland and fat.

Disease relevance. Cholestasis, progressive familial intrahepatic, 6 (PFIC6) [MIM:619484] An autosomal recessive form of progressive cholestasis, a disorder characterized by early onset of cholestasis that progresses to hepatic fibrosis, cirrhosis, and end-stage liver disease. PFIC6 patients have elevated liver transaminases and congenital diarrhea. The disease is caused by variants affecting the gene represented in this entry.

Induction. Positively regulated via NR1H4/FXR in adrenal gland, kidney and intestine.

Similarity. Belongs to the OST-alpha family.

RefSeq proteins (1): NP_689885* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005178	Ostalpha/TMEM184C	Family

Pfam: PF03619

Catalyzed reactions (Rhea), 11 shown:

• prostaglandin E2(out) = prostaglandin E2(in) (RHEA:50984)
• taurocholate(out) = taurocholate(in) (RHEA:71703)
• estrone 3-sulfate(out) = estrone 3-sulfate(in) (RHEA:71835)
• dehydroepiandrosterone 3-sulfate(out) = dehydroepiandrosterone 3-sulfate(in) (RHEA:71839)
• tauroursodeoxycholate(out) = tauroursodeoxycholate(in) (RHEA:71843)
• glycoursodeoxycholate(out) = glycoursodeoxycholate(in) (RHEA:71847)
• glycocholate(out) = glycocholate(in) (RHEA:71851)
• taurochenodeoxycholate(out) = taurochenodeoxycholate(in) (RHEA:71855)
• glycochenodeoxycholate(out) = glycochenodeoxycholate(in) (RHEA:71859)
• taurodeoxycholate(out) = taurodeoxycholate(in) (RHEA:71863)
• glycodeoxycholate(out) = glycodeoxycholate(in) (RHEA:71867)

UniProt features (19 total): topological domain 8, transmembrane region 7, sequence variant 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9UO2	ELECTRON MICROSCOPY	2.6
9LJG	ELECTRON MICROSCOPY	2.64
9LJH	ELECTRON MICROSCOPY	2.73
9UO1	ELECTRON MICROSCOPY	2.9
9UNV	ELECTRON MICROSCOPY	3.12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UW1-F1	82.38	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 330

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-159418	Recycling of bile acids and salts

MSigDB gene sets: 107 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_ACID_SECRETION, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SECRETION, GOBP_BILE_ACID_AND_BILE_SALT_TRANSPORT, SANSOM_APC_TARGETS_DN, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT, SABATES_COLORECTAL_ADENOMA_DN, VECCHI_GASTRIC_CANCER_EARLY_DN, ACEVEDO_LIVER_CANCER_UP, GOBP_LIPID_LOCALIZATION, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK

GO Biological Process (4): bile acid and bile salt transport (GO:0015721), bile acid secretion (GO:0032782), lipid transport (GO:0006869), transmembrane transport (GO:0055085)

GO Molecular Function (5): bile acid transmembrane transporter activity (GO:0015125), transmembrane transporter activity (GO:0022857), protein homodimerization activity (GO:0042803), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (6): endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), protein-containing complex (GO:0032991), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Bile acid and bile salt metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monocarboxylic acid transport	2
transport	2
protein dimerization activity	2
lipid transport	1
organic hydroxy compound transport	1
acid secretion	1
lipid localization	1
cellular process	1
bile acid and bile salt transport	1
carboxylic acid transmembrane transporter activity	1
lipid transmembrane transporter activity	1
transporter activity	1
transmembrane transport	1
identical protein binding	1
binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
cellular anatomical structure	1
basal plasma membrane	1
plasma membrane region	1
cellular_component	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

899 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC51A	SLC51B	Q86UW2	999
SLC51A	ABCC3	O15438	907
SLC51A	CYP7A1	P22680	902
SLC51A	SLC10A2	Q12908	881
SLC51A	FGF19	O95750	873
SLC51A	FABP6	P51161	810
SLC51A	ABCB11	O95342	808
SLC51A	SLC10A1	Q14973	797
SLC51A	NR1H4	Q96RI1	784
SLC51A	NR0B2	Q15466	735
SLC51A	CYP8B1	Q9UNU6	716
SLC51A	ABCB4	P21439	649
SLC51A	GPBAR1	Q8TDU6	623
SLC51A	ABCC2	Q92887	616
SLC51A	SLCO1A2	P46721	610

IntAct

14 interactions, top by confidence:

A	B	Type	Score
ATXN1	SLC51A	psi-mi:“MI:0915”(physical association)	0.670
SLC51A	DNAJC30	psi-mi:“MI:0915”(physical association)	0.560
SLC51A	TMEM63A	psi-mi:“MI:0914”(association)	0.530
SLC51A	TNPO2	psi-mi:“MI:0914”(association)	0.350
DNAJC30	SLC51A	psi-mi:“MI:0915”(physical association)	0.000
SLC51A	ATXN1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (52): ANO6 (Affinity Capture-MS), TMEM63A (Affinity Capture-MS), UBB (Affinity Capture-MS), FAM8A1 (Affinity Capture-MS), KIAA1715 (Affinity Capture-MS), DNAJC30 (Two-hybrid), TMEM63A (Affinity Capture-MS), ANO6 (Affinity Capture-MS), UBB (Affinity Capture-MS), ATP1B1 (Affinity Capture-MS), ATR (Affinity Capture-MS), KIAA1524 (Affinity Capture-MS), CNIH4 (Affinity Capture-MS), COG3 (Affinity Capture-MS), COG4 (Affinity Capture-MS)

ESM2 similar proteins: A2VE13, A4K2N5, A4K2W1, B8BPI2, E1BY51, O09117, O09198, O35682, O62646, O88662, O89104, P21145, Q04941, Q10EJ2, Q16563, Q1RMQ3, Q28296, Q3URJ8, Q3ZBY0, Q5R6H1, Q5RAI2, Q5VXT5, Q64349, Q6DHB5, Q6GPN9, Q6P0C6, Q6P742, Q6VBQ5, Q6Y1E2, Q78S06, Q86TG1, Q86UW1, Q8BI08, Q8CJ61, Q8IZ96, Q8IZR5, Q8N2H4, Q8N8D7, Q91WN2, Q95MN6

Diamond homologs: A9ULC7, Q3T124, Q66I08, Q86UW1, Q8R000, Q90YM5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

88 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	45
Likely benign	32
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1199252	NM_152672.6(SLC51A):c.556C>T (p.Gln186Ter)	Pathogenic

SpliceAI

2750 predictions. Top by Δscore:

Variant	Effect	Δscore
3:196216746:CCCAG:C	donor_gain	1.0000
3:196216749:AGG:A	donor_loss	1.0000
3:196216751:G:GG	donor_gain	1.0000
3:196216751:GTAA:G	donor_loss	1.0000
3:196226963:A:AG	acceptor_gain	1.0000
3:196226963:AGCC:A	acceptor_loss	1.0000
3:196226964:G:GG	acceptor_gain	1.0000
3:196226964:GCCC:G	acceptor_gain	1.0000
3:196226964:GCCCT:G	acceptor_gain	1.0000
3:196227101:G:GT	donor_gain	1.0000
3:196228918:GAC:G	donor_gain	1.0000
3:196228921:G:GG	donor_gain	1.0000
3:196228928:GGGA:G	donor_gain	1.0000
3:196228929:GGA:G	donor_gain	1.0000
3:196228929:GGAG:G	donor_gain	1.0000
3:196228930:GA:G	donor_gain	1.0000
3:196228930:GAG:G	donor_gain	1.0000
3:196228932:G:GG	donor_gain	1.0000
3:196228938:G:T	donor_gain	1.0000
3:196239540:AACAT:A	donor_loss	1.0000
3:196239541:ACAT:A	donor_loss	1.0000
3:196239542:CATA:C	donor_loss	1.0000
3:196239543:ATAC:A	donor_loss	1.0000
3:196239544:TACC:T	donor_loss	1.0000
3:196239545:A:AC	donor_gain	1.0000
3:196239545:A:T	donor_loss	1.0000
3:196239546:C:CC	donor_gain	1.0000
3:196239557:T:TA	donor_gain	1.0000
3:196239557:TCCGG:T	donor_gain	1.0000
3:196239583:T:TA	donor_gain	1.0000

AlphaMissense

2173 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:196229981:T:A	W234R	0.969
3:196229981:T:C	W234R	0.969
3:196227694:T:A	W107R	0.968
3:196227694:T:C	W107R	0.968
3:196233084:T:A	I303K	0.950
3:196232488:T:C	C284R	0.942
3:196228230:T:C	C160R	0.941
3:196227105:A:C	S92R	0.940
3:196227107:C:A	S92R	0.940
3:196227107:C:G	S92R	0.940
3:196227689:G:A	G105D	0.937
3:196229957:G:C	G226R	0.936
3:196229958:G:A	G226D	0.936
3:196227679:T:C	C102R	0.935
3:196232445:G:C	Q269H	0.934
3:196232445:G:T	Q269H	0.934
3:196228164:T:C	F138L	0.932
3:196228166:T:A	F138L	0.932
3:196228166:T:G	F138L	0.932
3:196227045:G:C	A72P	0.931
3:196227083:G:C	K84N	0.931
3:196227083:G:T	K84N	0.931
3:196229976:C:A	A232D	0.931
3:196227688:G:C	G105R	0.928
3:196232488:T:A	C284S	0.927
3:196232489:G:C	C284S	0.927
3:196229939:T:A	W220R	0.926
3:196229939:T:C	W220R	0.926
3:196232489:G:A	C284Y	0.926
3:196232490:T:G	C284W	0.925

dbSNP variants (sampled 300 via entrez): RS1000010696 (3:196228047 C>T), RS1000047318 (3:196219465 G>A), RS1000307330 (3:196233508 C>T), RS1000755994 (3:196216863 A>G), RS1000915693 (3:196231916 A>C,G), RS1001240264 (3:196232344 C>T), RS1001444234 (3:196217710 G>A), RS1001860096 (3:196227415 C>T), RS1001971259 (3:196221918 C>A,G), RS1001977482 (3:196223253 T>G), RS1002043954 (3:196223276 A>G), RS1002046423 (3:196233497 G>A), RS1002484448 (3:196217686 AAAGGAAGG>A,AAAGG,AAAGGAAGGAAGG), RS1002503554 (3:196233861 C>G), RS1002547691 (3:196228444 AG>A)

Disease associations

OMIM: gene MIM:612084 | disease phenotypes: MIM:619484

GenCC curated gene-disease

Disease	Classification	Inheritance
cholestasis, progressive familial intrahepatic, 6	Limited	Unknown

Mondo (1): cholestasis, progressive familial intrahepatic, 6 (MONDO:0030360)

Orphanet (0):

HPO phenotypes

12 total (12 of 12 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000978	Bruising susceptibility
HP:0001405	Periportal fibrosis
HP:0001406	Intrahepatic cholestasis
HP:0001508	Failure to thrive
HP:0002028	Chronic diarrhea
HP:0002908	Conjugated hyperbilirubinemia
HP:0002910	Elevated circulating hepatic transaminase concentration
HP:0003155	Elevated circulating alkaline phosphatase concentration
HP:0003593	Infantile onset
HP:0011888	Bleeding requiring red cell transfusion
HP:0030948	Elevated gamma-glutamyltransferase level

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST012020_600	Serum metabolite levels	1.000000e-21
GCST012020_601	Serum metabolite levels	6.000000e-11
GCST012020_602	Serum metabolite levels	6.000000e-11
GCST012020_603	Serum metabolite levels	2.000000e-20
GCST012021_1	Serum metabolite levels	2.000000e-20
GCST012021_48	Serum metabolite levels	1.000000e-21
GCST012021_49	Serum metabolite levels	6.000000e-11
GCST012021_50	Serum metabolite levels	6.000000e-11

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2073724 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC51 family of steroid-derived molecule transporters

CTD chemical–gene interactions

76 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Chenodeoxycholic Acid	increases expression, affects binding, decreases reaction, decreases expression, increases reaction (+2 more)	10
Deoxycholic Acid	affects cotreatment, increases expression	4
bisphenol A	decreases methylation, increases expression, affects expression, affects cotreatment, increases methylation	3
GW 4064	decreases reaction, increases expression	3
Glycochenodeoxycholic Acid	affects cotreatment, increases expression, affects binding, decreases reaction, increases uptake	3
Glycocholic Acid	affects binding, decreases reaction, increases uptake, affects cotreatment, increases expression	3
Cyclosporine	decreases expression	3
Benzo(a)pyrene	decreases expression, decreases methylation	2
Calcitriol	affects cotreatment, decreases expression	2
Glycodeoxycholic Acid	affects cotreatment, increases expression	2
Lithocholic Acid	increases expression	2
Nickel	increases expression	2
Triclosan	affects cotreatment, increases expression, decreases expression	2
Valproic Acid	affects expression, decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
fluxapyroxad	decreases expression	1
lasiocarpine	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt	affects cotreatment, increases expression	1
chlortoluron	decreases expression	1
deoxynivalenol	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases abundance, increases expression	1
tri-o-cresyl phosphate	decreases expression	1
benzo(e)pyrene	decreases methylation	1
epigallocatechin gallate	decreases reaction, increases expression	1
propiconazole	decreases expression	1
di-n-butylphosphoric acid	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2078563	Functional	TP_TRANSPORTER: cell accumulation in OST-expressing oocytes	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. — J Biol Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4TZ	HuH7-SLC51A-KO-c1	Cancer cell line	Male
CVCL_D4U0	HuH7-SLC51A-KO-c2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.